Skip to Main Content

A new CRISPR startup — backed by some big names in venture capital — is planning to develop gene-editing treatments that can insert a genetic sequence of any length, at any location in the DNA strand, according to industry insiders and documents.

The biotech is called Tome Biosciences, and it hopes to write the next chapter in genomic medicines. It’s backed by Arch Venture Partners, Andreessen Horowitz, and the Longwood Fund, which have closed a Series A round of financing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment